J. Oesterling

发表

Understanding artificial neural networks and exploring their potential applications for the practicing urologist.

J. Wei, Z. Zhang, S. Barnhill, 1998, Urology.

Interpreting results of prostate-specific antigen testing for early detection of prostate cancer

J. Oesterling, M. Barry, J. Meigs, 1996, Journal of General Internal Medicine.

Measurement of serum prostate specific antigen using IMx prostate specific antigen assay.

J. Oesterling, H. Zincke, G. Klee, 1994, The Journal of urology.

Does the mode of questionnaire administration affect the reporting of urinary symptoms?

H A Guess, J. Oesterling, H. Guess, 1995, Urology.

Analysis and presentation

Richard Sylvester, J. Oesterling, A. Taube, 1997 .

Using prostate-specific antigen to eliminate the staging radionuclide bone scan.

J. Oesterling, Cheryl T. Lee, J E Oesterling, 1997, The Urologic clinics of North America.

Recommendations of the First MichiganConference on Prostate Cancer

J. Oesterling, I. Thompson, G. Swanson, 1996 .

Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications.

J. Oesterling, J. E. Oesterling, 1995, Urology.

Megestrol acetate for the prevention of hot flashes.

J. O'fallon, J. Oesterling, C. Loprinzi, 1994, The New England journal of medicine.

The prevalence of prostatism: a population-based survey of urinary symptoms.

J. Oesterling, C. Chute, H. Guess, 1993, The Journal of urology.

Natural history of prostatism: worry and embarrassment from urinary symptoms and health care-seeking behavior.

J. Oesterling, C. Chute, R. Roberts, 1994, Urology.

A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men.

J. Oesterling, C. Chute, H. Guess, 1993, Archives of family medicine.

The natural history of prostatism: the effects of non-response bias.

J. Oesterling, C. Chute, H. Guess, 1994, International journal of epidemiology.

The management of renal angiomyolipoma.

E. Fishman, J. Oesterling, E. Fishman, 1986, The Journal of urology.

Metachronous bilateral Wilms tumor. Report of longest-known survivor and guidelines for conservative management.

J. Oesterling, R. Jeffs, 1987, Urology.

Prostate‐specific antigen and prostate cancer

J. Oesterling, 1992 .

The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration.

D. Bostwick, J. Oesterling, R. Myers, 1995, Urology.

Prostate-specific antigen detected prostate cancer: pathological characteristics of ultrasound visible versus ultrasound invisible tumors.

D. Bostwick, J. Oesterling, H. Zincke, 1995, European urology.

Prostate‐specific antigen: Establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation, and time on serum concentrations

J. Oesterling, E. Bergstralh, G. Klee, 1992, The Prostate.

Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.

J. Oesterling, D. Chan, P. Walsh, 1987, Clinical chemistry.

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes.

J. Oesterling, M. Barry, C. Coley, 1995, Urology.

The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration.

J. Oesterling, M. Tchetgen, J. E. Oesterling, 1997, The Urologic clinics of North America.

Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists.

J. Oesterling, M. Barry, R. Roberts, 1998, The American journal of medicine.

Predictive properties of serum-prostate-specific antigen testing in a community-based setting.

J. Oesterling, S. Katusic, H. Guess, 1996, Archives of internal medicine.

Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study.

J. Oesterling, C. Roehrborn, P. Narayan, 1998, Urology.

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

A W Partin, M W Kattan, M. Kattan, 1997, JAMA.

Influence of age and endocrine factors on the volume of benign prostatic hyperplasia.

J. Oesterling, A. Partin, P. Walsh, 1991, The Journal of urology.

Diagnosis and Treatment of Benign Prostatic Hyperplasia: Practice Patterns of Primary Care Physicians

J. Oesterling, M. Barry, R. Roberts, 1997, Journal of General Internal Medicine.

Squamous cell carcinoma of the scrotum: long-term followup of 14 patients.

J. Oesterling, G. Farrow, P. Andrews, 1991, The Journal of urology.

Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.

C G Chute, G G Klee, J. Oesterling, 1995, JAMA.

Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?

J. Oesterling, E. Bergstralh, D. Bilhartz, 1991, The Journal of urology.

Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration.

J. Oesterling, E. Bergstralh, W. Glenski, 1993, Urology.

In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples.

J. Oesterling, H. Lilja, U. Stenman, 1996, Urology.

Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.

J. Oesterling, A. Partin, P. Walsh, 1996, The Journal of urology.

Benign Prostatic Hyperplasia: Diagnosis and Treatment

David M. Eddy, Vic Hasselblad, John H. Wasson, 1998 .

Adverse effects of medications on urinary symptoms and flow rate: a community-based study.

J. Oesterling, H. Guess, M. Lieber, 1996, Journal of clinical epidemiology.

Computerized tomography in evaluation of transitional cell carcinoma in bladder diverticula.

J. Oesterling, S. Goldman, F. Lowe, 1989, Urology.

Re: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma.

J. Oesterling, H. Guess, S. Jacobsen, 1994, The Journal of urology.

BLADDER NECK-SPARING TECHNIQUE ADVERSELY AFFECTS ANTI-TUMOR EFFICACY OF RADICAL PROSTATECTOMY IN PATHOLOGIC T3a PROSTATE CANCER

John T. Wei, J. Oesterling, J. Montie, 1999 .

Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate.

J. Oesterling, H. Lilja, H. Zincke, 1996, Urology.

PSA Screening and Prostate Cancer Incidence-Reply

J. Oesterling, C. Chute, E. Bergstralh, 1996 .

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia.

A. Hillman, J. Oesterling, C. Roehrborn, 1996, Urology.

Urinary symptom and quality of life questions indicative of obstructive benign prostatic hyperplasia. Results of a pilot study.

R. Epstein, J. Oesterling, C. Chute, 1991, Urology.

Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy.

J. Oesterling, G. Klee, H. Ruckle, 1994, Mayo Clinic proceedings.

Influence of patient age on the serum PSA concentration. An important clinical observation.

J. Oesterling, W. Cooner, H. Guess, 1993, The Urologic clinics of North America.

The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia.

J. Oesterling, D. Chan, A. Partin, 1989, The Journal of urology.

Prostate-specific antigen and androgen deprivation therapy

J. Oesterling, H. Ruckle, 2004, World Journal of Urology.

Prostate-specific antigen and prostatic acid phosphatase: biomolecular and physiologic characteristics.

D. Tindall, J. Oesterling, D. Bilhartz, 1991, Urology.

LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia.

J. Oesterling, 1991, Journal of andrology.

Benign prostatic hyperplasia: A review of its histogenesis and natural history

J. Oesterling, J. E. Oesterling, 1996, The Prostate. Supplement.

The origin and development of benign prostatic hyperplasia. An age-dependent process.

J. Oesterling, J. E. Oesterling, 1991, Journal of andrology.

Anaplastic sarcoma arising in a mature metachronous bilateral Wilms' tumor after irradiation and chemotherapy spontaneous versus induced malignant change

J. Oesterling, R. Jeffs, B. Leventhal, 1987, Cancer.

Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study.

J. Oesterling, K. Cooney, E. Lange, 1998, Journal of the National Cancer Institute.

Age-specific reference ranges for serum PSA.

J. Oesterling, 1996, The New England journal of medicine.

Sexual Function of Men Ages 40 to 79 Years: The Olmsted County Study of Urinary Symptoms and Health Status Among Men

J. Oesterling, C. Chute, H. Guess, 1995, Journal of the American Geriatrics Society.

Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial.

J. Oesterling, H. Guess, E. Stoner, 1993, The Urologic clinics of North America.

Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms.

J. Oesterling, C. Chute, H. Guess, 1993, Urology.

Serum percent-free PSA does not predict extraprostatic spread of prostate cancer.

J. Oesterling, W. Henricks, D. Giacherio, 1998, American journal of clinical pathology.

Cancer of the Prostate-Reply

J. Oesterling, 1992 .

A prospective randomized comparison of epidural infusion of fentanyl and intravenous administration of morphine by patient-controlled analgesia after radical retropubic prostatectomy.

J. O. Welna, J. Oesterling, M. Blute, 1992, Mayo Clinic proceedings.

Age-specific reference ranges for serum prostate-specific antigen.

J. Oesterling, T. D. Richardson, 1997, The Urologic clinics of North America.

THE EFFECT OF PROSTATITIS, URINARY RETENTION, EJACULATION, AND AMBULATION SPECIFIC ANTIGEN CONCENTRATION ON THE SERUM PROSTATE-

J. Oesterling, M. Tchetgen, 1997 .

Sustained, substantially increased concentration of prostate-specific antigen in the absence of prostatic malignant disease: an unusual clinical scenario.

J. Oesterling, R. Malek, J. F. Myrtle, 1992, Mayo Clinic proceedings.

Long-term autopsy findings following radical prostatectomy.

J. Oesterling, P. Walsh, J. Epstein, 1987, Urology.

The North American experience with the UroLume endoprosthesis as a treatment for benign prostatic hyperplasia: long-term results. The North American UroLume Study Group.

J. Oesterling, S. Kaplan, M. Chancellor, 1994, Urology.

Original Articles PROSTATIC INTRAEPITHELIAL NEOPLASM IS A RISK FACTOR FOR ADENOCARCINOMA: PREDICTIVE ACCURACY IN NEEDLE BIOPSIES

D. Bostwick, J. Oesterling, P. Wollan, 1996 .

J. Oesterling, C. Chute, W. Garraway, 1993, The Journal of urology.

Prostate-specific antigen density : Prostate-specific antigen: the best prostatic tumor marker

J. Oesterling, M. Beduschi, 1997 .

Frozen section detection of lymph node metastases in prostatic carcinoma: accuracy in grossly uninvolved pelvic lymphadenectomy specimens.

J. Oesterling, P. Walsh, J. Epstein, 1986, The Journal of urology.

Neurofibromatosis with involvement of the prostate gland.

A. K. Chung, J. Oesterling, G. Poland, 1996, Urology.

Development of a highly sensitive immunochemiluminometric assay for prostate-specific antigen.

J. Oesterling, G. Klee, C. Preissner, 1994, Urology.

Hormonal Therapy of Prostate Cancer: Limitations in the Total Androgen Ablation Concept

J. Oesterling, D. S. Coffey, J. Isaacs, 1988 .

Advanced small cell carcinoma of the bladder successful treatment with combined radical cystoprostatectomy and adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

J. Oesterling, F. Marshall, J. Epstein, 1990, Cancer.

Transesophageal echocardiography in renal cell carcinoma: an accurate diagnostic technique for intracaval neoplastic extension.

C. V. Peterson, J. Oesterling, F. Marshall, 1991, The Journal of urology.

The volume and anatomical location of residual tumor in radical prostatectomy specimens removed for stage A1 prostate cancer.

J. Oesterling, P. Walsh, J. Epstein, 1988, The Journal of urology.

The Use of Prosthetic Stents in Tracheobronchial, Gastrointestinal, and Genitourinary Diseases

R. W. Hughes, J. Oesterling, D. Cortese, 1994, Diagnostic and therapeutic endoscopy.

Abdominal catheter holder to maintain controlled urethral catheter tension post transurethral resection of prostate.

J. Oesterling, 1992, Urology.

Computerized tomography in diagnosis of bladder rupture.

E. Fishman, J. Oesterling, F. Lowe, 1989, Urology.

Splenosis presenting as a left renal mass indistinguishable from renal cell carcinoma.

J. Oesterling, B. King, D. B. Bock, 1991, The Journal of urology.

Prostate specific antigen: a decade of discovery--what we have learned and where we are going.

J. Oesterling, A. Partin, A. Partin, 1999, The Journal of urology.

Use of prostate-specific antigen, Gleason score, and digital rectal examination in staging patients with newly diagnosed prostate cancer.

J. Oesterling, M. Resnick, M. A. Rees, 1997, The Urologic clinics of North America.

Prediction of capsular perforation and seminal vesicle invasion in prostate cancer.

D. Bostwick, J. Oesterling, E. Bergstralh, 1996, The Journal of urology.

The effect of finasteride on prostate specific antigen: review of available data.

J. Oesterling, H. Guess, E. Stoner, 1996, The Journal of urology.

The role of community-based longitudinal studies in evaluating treatment effects. Example: benign prostatic hyperplasia.

J. Oesterling, C. Chute, H. Guess, 1995, Medical care.

Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen.

J. Oesterling, H. Lilja, K. Pettersson, 1994, Urology.

Prostate-specific antigen: critical issues for the practicing physician.

J. Oesterling, G. Klee, H. Ruckle, 1994, Mayo Clinic proceedings.

Prognostic implications of prostate-specific antigen in patients with locally advanced prostate cancer treated with high energy neutron beam therapy: preliminary results.

J. Oesterling, L. Cohen, F. Hendrickson, 1993, Urology.

Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade.

J. Oesterling, H. Zincke, J. Larson-Keller, 1993, Urology.

Prostate-specific antigen, digital rectal examination, and transrectal ultrasonography: their roles in diagnosing early prostate cancer.

J. Oesterling, M. R. Cupp, J. E. Oesterling, 1993, Mayo Clinic proceedings.

The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study.

J. Oesterling, E. Bergstralh, F. Chybowski, 1992, The Journal of urology.

Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.

J. Oesterling, J E Oesterling, J. E. Oesterling, 1991, The Journal of urology.

Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration.

J. Oesterling, H. Zincke, G. Farrow, 1993, Urology.

Prostate specific antigen. Its role in the diagnosis and staging of prostate cancer

J. Oesterling, Joseph E. Oesterling, J. E. Oesterling, 1995 .

Branched, struvite calculus and clearcell carcinoma in same kidney

J. Oesterling, J. W. Segura, L. Kerr, 1990 .

Benign prostatic hyperplasia. Medical and minimally invasive treatment options.

J. Oesterling, J E Oesterling, J. E. Oesterling, 1995, The New England journal of medicine.

Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group.

J. Oesterling, J. Waldstreicher, T. Krarup, 1997, Urology.

Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group.

J. Oesterling, J. Waldstreicher, T. Krarup, 1997, Urology.

Non-germ cell tumors of testis.

J. Oesterling, G. Farrow, J. Dilworth, 1991, Urology.

Real-time, multiplanar computerized tomography: a new diagnostic modality used in the detection and endoscopic removal of a distal ureteral fibroepithelial polyp and adjacent calculus.

E. Fishman, J. Oesterling, H. Y. Liu, 1989, The Journal of urology.

The Relationship Between Prostatic Intraepithelial Neoplasia and Prostate Cancer: Critical Issues

J. Oesterling, J. Macoska, M. Häggman, 1997 .

Prostate‐specific antigen and diagnosing early malignancies of the prostate

J. Oesterling, J. E. Oesterling, 1992, Journal of cellular biochemistry. Supplement.

Age-specific reference ranges for serum prostate-specific antigen.

J. Oesterling, J E Oesterling, 1995, The Canadian journal of urology.

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

J. Oesterling, D. Chan, P. Walsh, 1988, The Journal of urology.

Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared.

J. Oesterling, D. Chan, P. Walsh, 1987, Clinical chemistry.

Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies.

D. Bostwick, J. Oesterling, P. Wollan, 1995, The Journal of urology.

Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.

J. Oesterling, R. Beduschi, M. Beduschi, 1998, Urology.

Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era.

J. Oesterling, H. Lilja, R. Wolfert, 1995, Urology.

Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.

P. Schellhammer, J. Oesterling, R. Vessella, 1997, Urology.

A new technique of using the in situ appendix as a catheterizable stoma in continent urinary reservoirs.

J. Oesterling, D. Canning, R. Jeffs, 1989, The Journal of urology.

The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older.

J. Oesterling, W. Cooner, S. Jacobsen, 1995, The Journal of urology.

Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

C G Chute, H A Guess, J. Oesterling, 1993, JAMA.

Update on the appropriate staging evaluation for newly diagnosed prostate cancer.

J. Oesterling, M. Miller, R. Veltri, 1997, The Journal of urology.

Review Article UPDATE ON THE APPROPRIATE STAGING EVALUATION FOR NEWLY DIAGNOSED PROSTATE CANCER

J. Oesterling, M. Miller, R. Veltri, 1997 .

The clinical usefulness of prostate specific antigen: update 1994.

J. Oesterling, A. Partin, J. E. Oesterling, 1994, The Journal of urology.

Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients.

J. Oesterling, G. Farrow, C. Hauzeur, 1992, The Journal of urology.

Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study.

J. Oesterling, K. Cooney, E. Lange, 1997, Journal of the National Cancer Institute.

Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.

J. Oesterling, E. Bergstralh, M. Blute, 1994, The Journal of urology.

An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx.

J. Oesterling, G. Wright, G. Beck, 1995, Urology.

Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer.

S. Cha, J. Oesterling, J. Earle, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate-specific antigen density.

J. Oesterling, J E Oesterling, M C Beduschi, 1997, The Urologic clinics of North America.

The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.

J. Oesterling, E. Bergstralh, E J Bergstralh, 1993, JAMA.

The importance of a successful initial bladder closure in the surgical management of classical bladder exstrophy: analysis of 144 patients treated at the Johns Hopkins Hospital between 1975 and 1985.

J. Oesterling, R. Jeffs, J. E. Oesterling, 1987, The Journal of urology.

Utilization of ileal conduit in construction of continent urinary reservoir.

J. Oesterling, J. Gearhart, 1990, Urology.

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.

J. Oesterling, D. Chan, A. Partin, 1990, The Journal of urology.

Homologous blood transfusion in patients with prostate cancer: no effect on tumor progression or survival.

J. Oesterling, M. Frydenberg, H. Zincke, 1994, Urology.

Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.

J. Oesterling, E. Bergstralh, J. Keller, 1991, The Journal of urology.

Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen.

J. Oesterling, H. Lilja, P. Abrahamsson, 1997, The Urologic clinics of North America.

Aromatase inhibition in the dog. II. Effect on growth, function, and pathology of the prostate.

J. Oesterling, D. S. Coffey, J. Strandberg, 1988, The Journal of urology.

Aromatase inhibition in the dog. I. Effect on serum LH, serum testosterone concentrations, testicular secretions and spermatogenesis.

J. Oesterling, D. S. Coffey, G. Niswender, 1988, The Journal of urology.

Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.

T. Stamey, J. Oesterling, H. Lilja, 1994, Scandinavian journal of urology and nephrology. Supplementum.

Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution.

J. Oesterling, E. Bergstralh, M. Blute, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A simple technique for removal of eroded penile prostheses.

J. Oesterling, 1989, The Journal of urology.

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program.

J. Oesterling, M. Barry, C. Coley, 1995, Urology.

Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup.

J. Oesterling, H. Zincke, E. Bergstralh, 1992, The Journal of urology.

Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens.

D. Bostwick, J. Oesterling, J. Earle, 1996, International journal of radiation oncology, biology, physics.

Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time.

J. Oesterling, H. Lilja, G. Klee, 1995, Urology.

Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.

D. Bostwick, J. Oesterling, H. Zincke, 1994, The Journal of urology.

Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.

D. Bostwick, J. Oesterling, E. Bergstralh, 1994, The Journal of urology.

Idiopathic myelofibrosis with myeloid metaplasia involving the renal pelves, ureters and bladder.

J. Oesterling, J. Earle, G. Farrow, 1992, The Journal of urology.

Xeroradiography and ultrasonography in the evaluation of a penile injury.

J. Oesterling, P. Albertsen, W. Bromberg, 1986, The Journal of urology.

CT findings in emphysematous cystitis.

E. Fishman, J. Oesterling, M. Bohlman, 1988, Urology.

PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors.

D. Bostwick, J. Oesterling, H. Zincke, 1993, The Urologic clinics of North America.

Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.

J. Oesterling, H. Lilja, U. Stenman, 1995, The Journal of urology.

Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate.

J. Oesterling, P. Walsh, J. Epstein, 1987, The Journal of urology.

Effect of several recruitment strategies on response rates at baseline in a prospective cohort investigation. The Olmsted County Study of Urinary Symptoms and Health Status among Men.

J. Oesterling, C. Chute, H. Guess, 1994, Annals of epidemiology.

Myxoid malignant fibrous histiocytoma of the bladder

J. Oesterling, J. Epstein, C. Brendler, 1990, Cancer.

Transitional cell carcinoma of the bladder in an adolescent with Turner's syndrome.

J. Oesterling, J. Epstein, J. Gearhart, 1987, The Journal of urology.

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.

J. Oesterling, H. Lilja, T. Piironen, 2000, The Journal of urology.

A model for the number of cores per prostate biopsy based on patient age and prostate gland volume.

J. Oesterling, B. Gillespie, J E Oesterling, 1998, The Journal of urology.

The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.

J. Oesterling, M. Tchetgen, 1995, The Urologic clinics of North America.

Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.

J. Oesterling, H. Lilja, U. Stenman, 1996, Urology.

Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study.

J. Oesterling, E. Crawford, N. Stone, 1996, Urology.

Newly diagnosed bulbar urethral strictures: etiology and outcome of various treatments.

J. Oesterling, V. Suman, T. J. Stormont, 1993, The Journal of urology.

Urolume endourethral prosthesis for the treatment of urethral stricture disease: long-term results of the North American Multicenter UroLume Trial.

J. Oesterling, G. Badlani, Arthur D. Smith, 1995, Urology.

Conservative management of a seminal vesicle abscess.

J. Oesterling, M. Kennelly, J. E. Oesterling, 1989, The Journal of urology.

The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis.

D. Bostwick, J. Oesterling, R. Myers, 1995, The Journal of urology.

Tumor volume versus percentage of specimen involved by tumor correlated with progression in stage A prostatic cancer.

J. Oesterling, P. Walsh, J. Epstein, 1988, The Journal of urology.

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategies.

J. Oesterling, M. Barry, C. Coley, 1995, Urology.

Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor.

J. Oesterling, H. Zincke, V. Suman, 1993, The Journal of urology.

Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing.

J. Oesterling, M. Beduschi, J. E. Oesterling, 1998, Urology.

A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia.

J. Oesterling, C. Roehrborn, R. Bruskewitz, 1998, The Journal of urology.

New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States.

J. Oesterling, H. Guess, M. Lieber, 1995, Archives of internal medicine.

A unified approach to early reconstructive surgery of the child with ambiguous genitalia.

J. Oesterling, J. Gearhart, R. Jeffs, 1987, The Journal of urology.

A simple substitute for a missing segment of the proximal anterior urethra.

J. Oesterling, H. J. Jewett, 1987, Journal of Urology.

Intravesical herniation of small bowel after bladder perforation.

J. Oesterling, S. Goldman, F. Lowe, 1987, The Journal of urology.

Staging of prostate cancer.

D. Bostwick, J. Oesterling, R. Myers, 1994, Seminars in surgical oncology.

Improved hemostasis during simple retropubic prostatectomy.

J. Oesterling, P. Walsh, 1990, The Journal of urology.

Scrotal surgery: a reliable method for the prevention of postoperative hematoma and edema.

J. Oesterling, 1990, The Journal of urology.

Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men.

J. Oesterling, H. Guess, M. Lieber, 1996, The Journal of urology.

Validation of a new quality of life questionnaire for benign prostatic hyperplasia.

J. Oesterling, C. Chute, D. Patrick, 1992, Journal of clinical epidemiology.

Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men.

J. Oesterling, H. Guess, N. Masumori, 1995, British journal of urology.

Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate.

C G Chute, H A Guess, J. Oesterling, 1995, The Journal of urology.

Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men?

J. Oesterling, C. Chute, H. Guess, 1995, Urology.

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

L K Lloyd, J. Oesterling, C. Roehrborn, 1996, Urology.

Ejaculation increases the serum prostate-specific antigen concentration.

J. Oesterling, M. Strawderman, S. Jacobsen, 1996, Urology.

Urinary diversion in hypospadias surgery 1987.

J. Oesterling, J. Gearhart, R. Jeffs, 1987, Urology.

Natural history of prostatism: urinary flow rates in a community-based study.

C. C. Chen, J. Oesterling, C. Chute, 1993, The Journal of urology.

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part I: Framing the debate.

J. Oesterling, M. Barry, C. Coley, 1995, Urology.

Reference ranges for serum prostate-specific antigen in black and white men without cancer.

J. Oesterling, J. Moul, M. Weinrich, 1998, Urology.

The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism.

J. Oesterling, P. Walsh, J. Epstein, 1986, The Journal of urology.

A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer.

J. Oesterling, M. Barry, F. J. Fowler, 1997, The Journal of urology.

Transurethral needle ablation (TUNATM): an overview of radiofrequency thermal therapy for the treatment of benign prostatic hyperplasia

J. Oesterling, M. Issa, J. E. Oesterling, 1996 .

Erratum: Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, Multicenter U.S. study (Urology (March 1998) 51 (415-421))

J. Oesterling, C. Roehrborn, P. Narayan, 1998 .

The effect of inhibition of aromatase enzyme activity on Leydig cell number and ultrastructure in beagles.

J. Oesterling, B. Zirkin, L. Ewing, 1988, Endocrinology.

Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications.

J. Oesterling, J. E. Oesterling, 1993, The Urologic clinics of North America.

Anterior rectal wall hematoma: complication of transrectal ultrasound-guided biopsy of prostate.

M. A. Seymour, J. Oesterling, 1992, Urology.

Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men.

H A Guess, J. Oesterling, R. Epstein, 1994, Urology.

Endocrine therapies for symptomatic benign prostatic hyperplasia.

J. Oesterling, J. E. Oesterling, 1994, Urology.

The periurethral glands do not significantly influence the serum prostate specific antigen concentration.

T. Stamey, J. Oesterling, E. Bergstralh, 1996, The Journal of urology.

Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists.

J. Oesterling, J. M. Monda, J. E. Oesterling, 1993, Mayo Clinic proceedings.

Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association.

J. Oesterling, M. Resnick, I. Thompson, 1995, The Journal of urology.

Radical prostatectomy: the retropubic approach.

J. Oesterling, J. E. Oesterling, 1996, Urology.

The definition and preoperative prediction of clinically insignificant prostate cancer.

D. Bostwick, J. Oesterling, E. Bergstralh, 1996, JAMA.

Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia.

J. Oesterling, M. Barry, M J Barry, 1994, The Journal of urology.

A permanent, epithelializing stent for the treatment of benign prostatic hyperplasia. Preliminary results.

J. Oesterling, J. E. Oesterling, 1991, Journal of andrology.

Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial.

J. Oesterling, C. Roehrborn, R. Padley, 1997, Urology.

Percent free prostate-specific antigen: entering a new era in the detection of prostate cancer.

J. Oesterling, A. Vashi, J. E. Oesterling, 1997, Mayo Clinic proceedings.

Prostate-Specific Antigen and Detecting Early Prostate Cancer: The Importance of Race and Patient Age

J. Oesterling, 1995 .

Diagnostic markers of prostate cancer: utility of prostate-specific antigen in diagnosis and staging.

J. Oesterling, C. T. Lee, C. T. Lee, 1995, Seminars in surgical oncology.

Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics.

J. Oesterling, E. Bergstralh, H. Zincke, 1993, Urology.

Prostate-specific antigen. Improving its ability to diagnose early prostate cancer.

J. Oesterling, J. E. Oesterling, 1992, JAMA.

Cigarette smoking and prostatism: a biphasic association?

J. Oesterling, C. Chute, R. Roberts, 1994, Urology.

The clinical usefulness of percent free-PSA.

A W Partin, J. Oesterling, A. Partin, 1996, Urology.

Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy

J. Oesterling, R. Beduschi, M. Beduschi, 2005, World Journal of Urology.

Screening digital rectal examination and prostate cancer mortality: a population-based case-control study.

J. Oesterling, E. Bergstralh, S. Katusic, 1998, Urology.

In Reply: RE:THE RELATIONSHIP BETWEEN PROSTATIC INTRAEPITHELIAL NEOPLASIA AND PROSTATE CANCER CRITICAL ISSUES

J. Oesterling, J. Macoska, M. Häggman, 1998 .

Autologous blood donation prior to anatomical radical retropubic prostatectomy: is it necessary?

J. Oesterling, C. Kleer, K. Wojno, 1998, Urology.

Have complication rates decreased after treatment for localized prostate cancer?

J. Oesterling, C. Roehrborn, M. Resnick, 1999, The Journal of urology.

Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy.

J. Oesterling, J. Ferguson, 1994, Urologic clinics of North America.

The Effects of Aromatase Inhibition on the Growth, Function and Pathology of the Canine Prostate

J. Oesterling, D. S. Coffey, L. Ewing, 1987 .

PSA leads the way for detecting and following prostate cancer.

J. Oesterling, 1993, Contemporary urology.

Influence of male hormones on rates of ethanol elimination in man

J. Oesterling, E. Mezey, J. Potter, 1988, Hepatology.

Multicenter comparison of the diagnostic performance of free prostate-specific antigen.

T. Stamey, J. Oesterling, D. Chan, 1996, Urology.

Medical Malpractice Implications of PSA Testing for Early Detection of Prostate Cancer

G. Annas, J. Oesterling, M. Barry, 1997, Journal of Law, Medicine & Ethics.

Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer.

J. Oesterling, M. Barry, P. Sershon, 1994, European urology.